Respiratory syncytial virus--the unrecognised cause of health and economic burden among young children in Australia
- PMID: 22010512
- DOI: 10.33321/cdi.2011.35.15
Respiratory syncytial virus--the unrecognised cause of health and economic burden among young children in Australia
Abstract
Respiratory syncytial virus (RSV) presents very similar to influenza and is the principle cause of bronchiolitis in infants and young children worldwide. Yet, there is no systematic monitoring of RSV activity in Australia. This study uses existing published data sources to estimate incidence, hospitalisation rates, and associated costs of RSV among young children in Australia. Published reports from the Laboratory Virology and Serology Reporting Scheme, a passive voluntary surveillance system, and the National Hospital Morbidity Dataset were used to estimate RSV-related age-specific hospitalisation rates in New South Wales and Australia. These estimates and national USA estimates of RSV-related hospitalisation rates were applied to Australian population data to estimate RSV incidence in Australia. Direct economic burden was estimated by applying cost estimates used to derive economic cost associated with the influenza virus. The estimated RSV-related hospitalisation rates ranged from 2.2-4.5 per 1,000 among children less than 5 years of age to 8.7-17.4 per 1,000 among infants. Incidence ranged from 110.0-226.5 per 1,000 among the under five age group to 435.0-869.0 per 1,000 among infants. The total annual direct healthcare cost was estimated to be between $24 million and $50 million. Comparison with the health burdens attributed to the influenza virus and rotavirus suggests that the disease burden caused by RSV is potentially much higher. The limitations associated with using a passive surveillance system to estimate disease burden, and the need to explore further assessments and to monitor RSV activity are discussed.
Similar articles
-
Economic burden of children hospitalized with respiratory syncytial virus infection in Spain, 2016-2019.Vaccine. 2025 Jan 1;43(Pt 2):126512. doi: 10.1016/j.vaccine.2024.126512. Epub 2024 Nov 7. Vaccine. 2025. PMID: 39515196
-
National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study.Lancet Respir Med. 2021 Feb;9(2):175-185. doi: 10.1016/S2213-2600(20)30322-2. Epub 2020 Sep 21. Lancet Respir Med. 2021. PMID: 32971018
-
The 2018 annual cost burden for children under five years of age hospitalised with respiratory syncytial virus in Australia.Commun Dis Intell (2018). 2022 Feb 16;46. doi: 10.33321/cdi.2022.46.5. Commun Dis Intell (2018). 2022. PMID: 35168504
-
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19. Lancet. 2022. PMID: 35598608 Free PMC article. Review.
-
Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.Lancet. 2024 Mar 30;403(10433):1241-1253. doi: 10.1016/S0140-6736(24)00138-7. Epub 2024 Feb 14. Lancet. 2024. PMID: 38367641
Cited by
-
Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries.Clin Dev Immunol. 2013;2013:917068. doi: 10.1155/2013/917068. Epub 2013 Jun 19. Clin Dev Immunol. 2013. PMID: 23861694 Free PMC article.
-
Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.J Glob Health. 2017 Jun;7(1):010412. doi: 10.7189/jogh.07.010412. J Glob Health. 2017. PMID: 28702175 Free PMC article.
-
Pediatric Respiratory and Enteric Virus Acquisition and Immunogenesis in US Mothers and Children Aged 0-2: PREVAIL Cohort Study.JMIR Res Protoc. 2021 Feb 12;10(2):e22222. doi: 10.2196/22222. JMIR Res Protoc. 2021. PMID: 33576746 Free PMC article.
-
An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.Vaccine. 2014 Nov 12;32(48):6485-92. doi: 10.1016/j.vaccine.2014.09.030. Epub 2014 Sep 28. Vaccine. 2014. PMID: 25269094 Free PMC article.
-
The clinical and etiological characteristics of influenza-like illness (ILI) in outpatients in Shanghai, China, 2011 to 2013.PLoS One. 2015 Mar 30;10(3):e0119513. doi: 10.1371/journal.pone.0119513. eCollection 2015. PLoS One. 2015. PMID: 25822885 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical